ImmuCell Corporation (ICCC)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $97.73M
Last updated: Nov 17, 2026 at 11:06 AM ET
ImmuCell Corporation (ICCC) Earnings: Report Dates and Results
ImmuCell (ICCC) is expected to report earnings on Mar 2, 2027. In the quarter ended Sep 30, 2026, ImmuCell reported EPS of $0.10. It beat the EPS estimate in 2 of the 8 most recent quarters that had an estimate.
Earnings
Performance (10Y)
Next Report
ICCC has an expected report date of Mar 2, 2027.
ICCC Earnings Call
The latest ICCC earnings call transcript on file is labeled 2026Q3.
Read the 2026Q3 transcriptEarnings History
Of the 8 quarters below that had an estimate, ICCC beat 2, missed 1 and matched 5. Revenue for the quarter ended Sep 30, 2026 was $8.04M, up 45.9% from $5.51M a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | $0.10 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Nov 12, 2026 | $8.04M |
| Jun 30, 2026 | $0.20 | N/A | N/A | N/A | N/A | +233.3% | N/A | N/A | Aug 13, 2026 | $7.19M |
| Mar 31, 2026 | $0.21 | N/A | N/A | N/A | N/A | +33.2% | N/A | N/A | May 14, 2026 | $10.36M |
| Dec 31, 2025 | -$0.31 | N/A | N/A | N/A | N/A | -646.7% | N/A | N/A | Mar 4, 2026 | $7.63M |
| Sep 30, 2025 | -$0.02 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Nov 13, 2025 | $5.51M |
| Jun 30, 2025 | $0.06 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Aug 14, 2025 | $6.44M |
| Mar 31, 2025 | $0.16 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | May 14, 2025 | $8.07M |
| Dec 31, 2024 | $0.06 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Feb 25, 2025 | $7.75M |
| Sep 30, 2024 | -$0.09 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Nov 13, 2024 | $6.01M |
| Jun 30, 2024 | -$0.20 | N/A | N/A | N/A | N/A | -208.9% | N/A | N/A | Aug 13, 2024 | $5.47M |
| Mar 31, 2024 | -$0.06 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | May 14, 2024 | $7.26M |
| Dec 31, 2023 | -$0.15 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Feb 27, 2024 | $5.10M |
| Sep 30, 2023 | -$0.12 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Nov 13, 2023 | $5.40M |
| Jun 30, 2023 | $0.18 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Aug 10, 2023 | $3.53M |
| Mar 31, 2023 | -$0.30 | N/A | N/A | N/A | N/A | -433.3% | N/A | N/A | May 11, 2023 | $3.45M |
| Dec 31, 2022 | -$0.32 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Feb 21, 2023 | $3.91M |
| Sep 30, 2022 | -$0.08 | N/A | N/A | N/A | N/A | -523.0% | N/A | N/A | Nov 21, 2022 | $4.80M |
| Jun 30, 2022 | -$0.09 | N/A | N/A | N/A | N/A | -550.0% | N/A | N/A | Aug 11, 2022 | $3.86M |
| Mar 31, 2022 | $0.09 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | May 12, 2022 | $6.00M |
| Dec 31, 2021 | -$0.01 | -$0.01 | N/A | 0.00% | In line | -133.3% | N/A | N/A | Feb 22, 2022 | $5.44M |
| Sep 30, 2021 | $0.02 | $0.02 | N/A | 0.00% | In line | N/A | N/A | N/A | Nov 15, 2021 | $5.15M |
| Jun 30, 2021 | $0.02 | $0.02 | N/A | 0.00% | In line | N/A | N/A | 0 up, 0 down | Aug 12, 2021 | $4.54M |
| Mar 31, 2021 | -$0.06 | -$0.06 | N/A | 0.00% | In line | N/A | N/A | 0 up, 0 down | May 13, 2021 | $4.11M |
| Dec 31, 2020 | $0.03 | -$0.04 | N/A | +175.00% | Beat | N/A | N/A | N/A | Feb 22, 2021 | $3.74M |
| Sep 30, 2020 | -$0.04 | -$0.08 | -$0.08 - -$0.08 | +50.00% | Beat | N/A | 1 | N/A | Nov 12, 2020 | $3.72M |
| Jun 30, 2020 | -$0.11 | -$0.10 | -$0.10 - -$0.10 | -10.00% | Miss | N/A | 1 | N/A | Aug 12, 2020 | $2.97M |
| Mar 31, 2020 | -$0.02 | -$0.02 | N/A | 0.00% | In line | -166.7% | N/A | N/A | May 13, 2020 | $4.91M |
| Dec 31, 2019 | -$0.06 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Feb 18, 2020 | $3.63M |
| Sep 30, 2019 | -$0.07 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Nov 11, 2019 | $2.97M |
| Jun 30, 2019 | -$0.09 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Aug 12, 2019 | $2.71M |
| Mar 31, 2019 | $0.03 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | May 13, 2019 | $4.41M |
| Dec 31, 2018 | -$0.19 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Feb 13, 2019 | $2.94M |
| Sep 30, 2018 | -$0.05 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Nov 13, 2018 | $2.15M |
| Jun 30, 2018 | -$0.15 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Aug 13, 2018 | $3.01M |
| Mar 31, 2018 | -$0.04 | N/A | N/A | N/A | N/A | -133.3% | N/A | N/A | May 14, 2018 | $2.88M |
| Dec 31, 2017 | -$0.05 | N/A | N/A | N/A | N/A | -906.5% | N/A | N/A | Feb 8, 2018 | $3.13M |
| Sep 30, 2017 | -$0.07 | N/A | N/A | N/A | N/A | -964.2% | N/A | N/A | Nov 13, 2017 | $2.00M |
| Jun 30, 2017 | -$0.05 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Aug 14, 2017 | $1.75M |
| Mar 31, 2017 | $0.12 | N/A | N/A | N/A | N/A | +4.6% | N/A | N/A | May 11, 2017 | $3.54M |
| Dec 31, 2016 | $0.01 | N/A | N/A | N/A | N/A | -93.2% | N/A | N/A | Feb 9, 2017 | $2.21M |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was -$0.11, after -$0.28 the year before. It was $0.13 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | -$0.11 | N/A |
| Dec 31, 2024 | -$0.28 | N/A |
| Dec 31, 2023 | -$0.39 | N/A |
| Dec 31, 2022 | -$0.40 | N/A |
| Dec 31, 2021 | -$0.03 | N/A |
| Dec 31, 2020 | -$0.14 | N/A |
| Dec 31, 2019 | -$0.19 | N/A |
| Dec 31, 2018 | -$0.43 | N/A |
| Dec 31, 2017 | -$0.05 | -139.4% |
| Dec 31, 2016 | $0.13 | N/A |
Earnings Calls
The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 4,100 words across 7 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q3 | Sep 30, 2026 | 4,113 | 7 | |
| 2026Q2 | Jun 30, 2026 | 4,072 | 8 | |
| 2026Q1 | Mar 31, 2026 | 3,678 | 7 | |
| 2025Q4 | Dec 31, 2025 | 3,210 | 4 | |
| 2025Q3 | Sep 30, 2025 | 3,357 | 7 | |
| 2025Q2 | Jun 30, 2025 | 4,583 | 6 | |
| 2025Q1 | Mar 31, 2025 | 4,068 | 7 | |
| 2024Q4 | Dec 31, 2024 | 2,809 | 4 |
2026Q3 Earnings Call
Opening remarks
Joe Diaz Investor Relations Consultant Thank you, operator. Good morning, and welcome. As the operator indicated, my name is Joe Diaz with Lytham Partners. We are the investor relations consulting firm for ImmuCell. I thank all of you for joining us today to discuss the unaudited earnings for the third quarter and nine months ended September 30, 2026. Listeners are reminded and cautioned that statements made by management during the course of this call include forward-looking statements, which include any statement that refers to future events or expected future results or predictions about steps the company plans to take in the future. These statements are not guarantees of performance and are subject to risks and uncertainties that could cause actual results, outcomes, or events to differ materially from those discussed today. Additional information regarding forward-looking statements and the risks and uncertainties that could impact future results, outcomes, or events is available under the cautionary note regarding forward-looking statements provided with the press release that the company filed last night, along with the company's other periodic filings with the SEC. Information discussed on today's call speaks only as of today, Friday, November 13, 2026. The company undertakes no obligation to update any information discussed on today's call. Please note that references to certain non-GAAP financial measures may be made during today's call. With that said, let me turn the call over to Olivier te Boekhorst, President and CEO of ImmuCell Corporation, for some opening remarks. Olivier?
Olivier te Boekhorst President and CEO Thanks, Joe, and good morning, everyone. It's my pleasure to welcome you today to the discussion of ImmuCell's results for the third quarter of 2026. Our discussion of results will be accompanied by a few key slides that are also part of our updated investor presentation. You can find that on our investor page, immucell.com/investors. I will start off today's call with a quick summary of ImmuCell's strategy, which we have developed and refined over the past year. We made the decision in December of 2025 to focus exclusively on First Defense, our bovine scours preventative product line, to take advantage of attractive market tailwinds. High calf values drive producer interest in effective preventatives, and we saw significant opportunity for growth in the U.S. and future international markets. We stopped investing in a new product for subclinical mastitis called Re-Tain, also driven by our contract manufacturer's inability to obtain GMP approval from the FDA. Our mission became to ensure we had sufficient supply to meet demand for First Defense and to restore our customers' confidence in that ability to supply after a protracted period of supply challenges leading to back orders. We invested in leadership, in expanding our commercial team, in colostrum sourcing capabilities, and importantly, in manufacturing.
Frequently Asked Questions About ICCC
When is ImmuCell's next earnings date?
ImmuCell's next earnings report is expected for Mar 2, 2027.
How often does ICCC beat earnings estimates?
ImmuCell beat the EPS estimate in 2 of the 8 most recent quarters that had an estimate, with an average surprise of +26.88%.
ICCC pages: Overview, Earnings, Financials, Valuation, Competitors